{"entity":{"id":"duo-o","kind":"trial","name":"DUO-O / ENGOT-ov46","aka":[],"tldr":"Adding immunotherapy and olaparib to bevacizumab slowed progression but has not improved survival, and the regimen is not approved.","summary":"DUO-O, also ENGOT-ov46, trial NCT03737643 sponsored by AstraZeneca and reported at ASCO 2023, tested adding durvalumab and olaparib to chemotherapy plus bevacizumab in newly diagnosed non-BRCA-mutated advanced ovarian cancer, and found that the combination slowed progression but has not improved survival, so the regimen is not approved. It randomised 1,130 patients, met its primary progression-free survival endpoint in the non-BRCA population for the durvalumab plus olaparib arm, but the interim overall survival analysis published in Annals of Oncology in 2025 showed no survival signal. Whether any subgroup of ovarian cancer benefits from first-line checkpoint blockade remains the open question.","status":"mixed","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT03737643","url":"https://clinicaltrials.gov/study/NCT03737643"},{"label":"OncLive on OS","url":"https://www.onclive.com/view/chemotherapy-plus-durvalumab-bevacizumab-and-olaparib-fails-to-offer-os-benefit-in-newly-diagnosed-non-tbrca-mutated-ovarian-cancer"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1","parp"],"drugs":["durvalumab","olaparib","bevacizumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03737643","phase":"3","setting":"Newly diagnosed non-BRCA-mutated advanced ovarian cancer: chemotherapy + bevacizumab + durvalumab, then durvalumab + bevacizumab ± olaparib maintenance, vs standard","sponsor":"AstraZeneca","result":"PFS HR 0.63; interim OS HR 0.95.","started":"2019-01-04","startedType":"actual","yearReported":2023,"enrolled":1130,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival (non-tBRCAm ITT)","primary":true,"unit":"HR","arms":[{"name":"Durvalumab + olaparib + bevacizumab"},{"name":"Bevacizumab + placebo"}],"hr":0.63,"ci":[0.52,0.76],"source":"https://ascopubs.org/doi/10.1200/JCO.2023.41.17_suppl.LBA5506"}]},"route":"/trials/duo-o/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"pairing":[{"id":"caution-pd1-first-line-ovarian","kind":"pairing","name":"Caution: checkpoint inhibitors in first-line ovarian cancer","route":"/pairings/caution-pd1-first-line-ovarian/"}]}}